Beta-naphthyl phosphate is an organic compound used in the study of enzyme activity, specifically alkaline phosphatase. It is a substrate for this enzyme, which hydrolyzes the phosphate group to produce beta-naphthol and inorganic phosphate. Beta-naphthol is a fluorescent compound, allowing for the detection and quantification of enzyme activity. The hydrolysis reaction is also used in clinical diagnostics, for example, in blood tests to assess liver function. The compound is synthesized via the reaction of beta-naphthol with phosphorus oxychloride. It is a colorless solid, typically stored as a solution in a solvent like ethanol or dioxane. '
beta-naphthyl phosphate: substrate for bovine kidney acid phosphatase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2-naphthyl dihydrogen phosphate : An aryl phosphate resulting from the formal condensation of phosphoric acid with 1 mol eq. of 2-naphthol. It is a substrate for phosphatase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 83133 |
| CHEMBL ID | 25431 |
| CHEBI ID | 91043 |
| SCHEMBL ID | 2344043 |
| MeSH ID | M0278706 |
| Synonym |
|---|
| beta-naphthyl phosphate |
| AKOS005438098 |
| STK330837 |
| naphthalen-2-yl dihydrogen phosphate |
| 2-naphthyl dihydrogen phosphate |
| CHEMBL25431 , |
| bdbm50112452 |
| phosphoric acid mono-naphthalen-2-yl ester |
| 13095-41-5 |
| einecs 236-011-4 |
| FT-0638985 |
| SCHEMBL2344043 |
| phosphoric acid mono-2-naphthyl ester |
| CHEBI:91043 |
| beta-naphthyl dihydrogen phosphate |
| phosphoric acid mono-beta-naphthyl ester |
| 2-naphthyl phosphate |
| DTXSID50926983 |
| Q27163037 |
| 2-naphthol phosphate |
| naphthalen-2-yldihydrogenphosphate |
| 2-naphthalenol, 2-(dihydrogen phosphate) |
| (naphthalen-2-yloxy)phosphonic acid |
| Role | Description |
|---|---|
| chromogenic compound | Colourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| aryl phosphate | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | IC50 (µMol) | 1,000.0000 | 0.0002 | 0.5335 | 10.0000 | AID205503 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID205503 | The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tyrosine kinase SH2 domain | 2002 | Bioorganic & medicinal chemistry letters, May-06, Volume: 12, Issue:9 | Small ligands interacting with the phosphotyrosine binding pocket of the Src SH2 protein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||